nach oben

Medical Oncology

Erschienen in:

01.09.2010 | Original Paper

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature

verfasst von: Halit Karaca, Ayhan Lale, Mustafa Dikilitas, Metin Ozkan, Ozlem Er

Erschienen in: Medical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor. İt has higher response rates and progression-free survival in patients with metastatic renal cell carcinoma (RCC) when compared with standard chemotherapy and interferon-α. We report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33-years-old man with metastatic RCC. At the sixth month of follow-up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life-threatening entity.

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed

Ganesh SP, Blaine K, Jacob R. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4(4):163–70.

Er O, Coşkun HS, Altınbaş M, et al. Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia. Urol Int. 2001;67:175–7.CrossRefPubMed

Warren WD, Utz DC, Kelalis PP. Concurrence of hypernephroma and hypercalcemia. Ann Surg. 1971;174:863–5.CrossRefPubMed

Mundy GR, Ibbotson KJ, D’Souza SM, et al. The hypercalcemia of cancer. N Engl J Med. 1984;310:1718–27.CrossRefPubMed

Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.CrossRefPubMed

Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005;23:240–55.

Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471–8.PubMed

Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37.PubMed

10.

Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757–66.CrossRefPubMed

11.

O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–605.CrossRefPubMed

12.

Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma (abstract no. LBA3). J Clin Oncol. 2006;24(Suppl 18):930.

13.

Escuider B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol. 1999;17:2039–43.

14.

Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–63.CrossRefPubMed

15.

Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115–24.CrossRefPubMed

16.

Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287–95.PubMed

17.

Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with percyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338–40.PubMed

18.

Newman E, Bouvet M, Borgehi S, Herold D, Deftos L. Causes of hypercalcemia in a population of military veterans in the United States. Endocr Pract. 2006;12(5):535–41.PubMed

19.

Lee C, Yang C, Lam K, et al. Hypercalcemia in the emergency department. Am J Med Sci. 2006;331(3):119–23.CrossRefPubMed

20.

Vassilopoulou-Sellin R, Newman B, Taylor S, Guinee V. Incidence of hypercalcemia in the patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309–12.CrossRefPubMed

21.

Papworth K, Grankvist K, Ljungberg B, Rasmuson T. Parathyroid hormone-related protein and serum calcium in patient with renal cell carcinoma. Tumour Biol. 2005;2(4):201–6.CrossRef

22.

Chasan SA, Pothel RL, Huben RP. Management and prognostic significance of hypercalcemia in renal cell carcinoma. Urology. 1989;33:167–71.CrossRefPubMed

23.

Endo I, Inoue D. Treatment of malignancy-associated hypercalcemia. Clin Calcium. 2006;16(4):373–9.

24.

Ritch PS. Treatment of cancer-related hypercalcemia. Semin Oncol. 1990;17:26–33.PubMed

25.

Pepper K, Jaowattana U, Starsiak MD, et al. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature. Soc Gen Int Med. 2007;22:1042–6.CrossRef

26.

Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–18.CrossRefPubMed

Titel: Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
verfasst von: Halit Karaca
Ayhan Lale
Mustafa Dikilitas
Metin Ozkan
Ozlem Er
Publikationsdatum: 01.09.2010
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-009-9327-4

Springer Medizin

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib

Postmenopausal bleeding as first sign of an acute myelogenous leukaemia: A case report and review of the literature

Interstitial lung disease in patients with small cell lung cancer

Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy

p53 codon 72 polymorphism and risk of cervical carcinoma in Moroccan women

Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie